Pantherna’s innovative platform focuses on developing advanced lipid nanoparticle (LNP) technologies for organ-specific and cell-selective delivery and expression of mRNA-based therapeutics. Through the tailored adjustment of our lipid nanoparticles, we already enable precise pharmacological targeting of diverse tissues. Our advanced LNP technologies for mRNA-based therapeutics, based on an optimized combination of PTX lipids, guarantee efficient mRNA release in target cells – for versatile and forward-thinking therapies that set new standards locally and systemically.
Public funding
Details
Pantherna is supported by public funding from the EU (EFRE). EFRE is provided by the State Brandenburg through the program “ProFIT”:
#80258140/ 41 ProFIT: „Vaskularspezifische Transportsysteme für Nukleinsäure in 16761 Hennigsdorf, Neuendorfstraße 20b“
Mit der Durchführung des AP#3, Thema: Untersuchung der in AP#1 erforschten Testformulierungen auf immunstimulierendes Potenzial anhand diverser Vergleichsmessungen von Lipid-und Polymer-Formulierungen“ (Zeitraum vom 15.4.2021-31.12.2022), wurde die Helmholtz-Zentrum hereon GmbH, [Institut für Aktive Polymere, Hereon Teltow, Abteilung Stammzellmodifikation und Biomaterialien, Haus M, Raum 202, Kantstr. 55, D-14513 Teltow] beauftragt.
Get in touch
Headquarters
Innovationsforum Hennigsdorf
Neuendorfstrasse 20b
D-16761 Hennigsdorf
Phone +49(0)3302-202 240-0
Fax: +49(0)3302-202 240-1
